CFRX stock forecast
Our latest prediction for ContraFect Corp.'s stock price was made on the Dec. 13, 2019 when the stock price was at 0.43$.
In the short term (2weeks), CFRX's stock price should underperform the market by -5.50%. During that period the price should oscillate between -13.15% and +20.40%.
In the medium term (3months), CFRX's stock price should underperform the market by -18.05%. During that period the price should oscillate between -45.08% and +43.78%.Get email alerts
Create a solid portfolio with CFRX
About ContraFect Corp.
ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a profit of 0.05$ per share.
The book value per share is -0.09$
Three months stock forecastDec. 13, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|